首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 製藥 > 快速發展的分子診斷產業的最新動向
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

快速發展的分子診斷產業的最新動向

Recent Advances in the Fast-Growing Molecular Diagnostics Industry

出版商 Decision Resources, Inc.
出版日期 2007年03月 商品編碼 50582
內容資訊 英文 28 Pages
價格
本報告書已不再販售

本報告已在2011年12月21日停止出版。

簡介

分子診斷與藥品研發有著比以往更加密切的關係。目前診斷及預後診斷仍扮演臨床醫療的補助性角色,但隨著規範當局的支援、治療方法開發及商業化的重要性增加等趨勢發展,分子診斷市場在今後可望以相當快的速度持續發展。

專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. (總公司:Massachusetts State),針對快速發展的分子診斷產業的最新動向進行調查分析,並系統整理調查結果後出版報告書 "Recent Advances in the Fast-Growing Molecular Diagnostics Industry" 。

本報告書內容包括:分子診斷3個階段的概要及分子診斷技術、平台、主要參與企業、專家的見解等。共計28頁的內容綱要摘記如下:

實施概要

概要

分子診斷產業的發展

分子診斷的3個階段

  • 第1階段:傳染病
  • 第2階段:血液篩檢
  • 第3階段:藥理基因組合試驗、基因檢查、預測試驗、根據指導手冊的診斷
    • 藥理基因組合試驗
    • 預測試驗
    • 基因檢查

專家對分子診斷的看法:未來趨勢

  • 根據指導手冊的診斷

分子診斷技術與平台

  • 分子診斷技術
    • PCR
    • DNA甲基化
    • RNA干預
  • 分子診斷平台
    • 微陣列及奈米陣列
    • 微流體
    • 多重分析

改變中的動向

  • 製藥企業與分子診斷企業之間的合作與購併
  • 來自規範當局的支援

分子診斷的規範環境與進化

分子診斷產業中的主要企業

  • Roche Diagnostics
  • Abbott Diagnostics
  • Bayer Diagnostics/Siemens Medical Solutions Group

市場發展預測

  • 針對傳染病藥的分子診斷
  • 分子診斷產業的第3個階段
  • 與研究機構及製藥企業/生物科技企業的合作
  • AmpliChip CYP450試驗
  • PGx診斷試驗
  • 分子試驗的比較
  • 製藥企業與分子診斷企業的合作
  • 診斷企業與技術企業的合作
  • 分子診斷市場中的購併
  • 分子診斷試驗增加可能產生的影響
  • 全球分子診斷市場的機會:2005年∼2010年
  • Celera Diagnostics目前及今後預定推出的分子診斷產品

  • 分子診斷產業的3個階段
  • 與學術/研究機構及製藥企業/生物科技企業合作帶動的成長:2002年∼2006年
  • 分子診斷技術與平台
  • 製藥企業/生物科技企業與分子診斷企業的相互關係
  • 分子診斷市場未來發展的多樣化

目錄

Abstract

Introduction

Molecular diagnostics (MDx) is becoming increasingly entwined with the development of pharmaceutical drugs. Initially, it was used in clinical settings to aid diagnosis, prognosis, and optimal treatment, but now, backed by regulatory authorities, it is becoming important in the development and commercialization of new and existing therapies. As a result, the MDx industry, already a multibillion-dollar market, will continue to expand at a significant pace.

Get the Answers You Need to Shape Your Strategy

The MDx market can be segmented into three phases: infectious diseases; blood screening; and pharmacogenomic testing, genetic testing, predictive testing, and companion diagnostics. Why does scope for greater innovation and greater sales potential lie in the third phase?

According to industry experts, polymerase chain reaction (PCR) technology will have the greatest impact on the MDx market. PCR enables researchers to amplify minute amounts of genetic material to billions of copies in a matter of hours through repeated cycles of duplication via the use of an enzyme called DNA polymerase or Taq polymerase. What big pharma company used PCR to become one of the most powerful leaders in the field of MDx?

Pharmaceutical companies have traditionally been reluctant to employ MDx (e.g., to identify biomarkers) to screen drug candidates during the R&D process for fear of reducing the potential target population. Why is this attitude changing?

Big pharmaceutical companies and smaller MDx companies are teaming up to produce MDx technologies. What alliances have been formed, and what products have been the result?

Scope

  • The three phases of MDx: infectious diseases; blood screening; and pharmacogenomic testing, genetic testing, predictive testing, and companion diagnostics.
  • MDx technologies: PCR, DNA methylation, and RNAi validation.
  • MDx platforms: Microarrays, nanoarrays, microfluidics, and multiplex assays.
  • Major players: Roche Diagnostics, Abbott Diagnostics, and Siemens Medical Solutions Group.
  • Expert Commentary: Dr. John Sninsky, vice president of discovery research at Celera, and Dr.David Speechly, Media and Investor Relations at Celera, discuss Celera’s involvement in MDx.

Companies Mentioned in This Spectrum Report

  • Abbott Diagnostics
  • Affymetrix
  • Alnylam Pharmaceuticals
  • Applera
  • Applied Biosystems
  • Benitec
  • BioForce Nanosciences
  • Biosite
  • Celera
  • Cepheid
  • Cetus
  • Chiron
  • deCode
  • Epigenomics AD
  • Genaco Biomedical Products
  • Genzyme
  • Illumina
  • International Therapeutics
  • Johns Hopkins University
  • School of Medicine
  • Johnson & Johnson
  • MetriGenix
  • Nanogen
  • Nanolink
  • Oncomethylome Sciences
  • Orion Genomics
  • Osmetech
  • PamGene
  • Qiagen
  • Randox
  • Roche Diagnostics
  • Siemens Medical Solutions
  • Group
  • Tepnel (formerly Orchid
  • Biosciences)
  • Third Wave Technologies

Table of Contents

  • Executive Summary
    • Strategic Considerations
    • Stakeholder Implications
  • Overview
  • The Evolution of the MDx Industry
  • The Three Phases of the MDx Industry
    • Phase One: Infectious Diseases
    • Phase Two: Blood Screening
    • Phase Three: Pharmacogenomic Testing, Genetic Testing, Predictive Testing, and
    • Companion Diagnostics
      • Pharmacogenomic Testing
      • Predictive Testing
      • Genetic Testing
  • Expert Commentary-MDx: Looking Ahead
    • Companion Diagnostics
  • MDx Technologies and Platforms
    • MDx Technologies
      • PCR
      • DNA Methylation
      • RNA Interference
    • MDx Platforms
      • Microarrays and Nanoarrays
      • Microfl uidics
      • Multiplex Assays
  • Changing Trends
    • Pharmaceutical/MDx Alliances and Acquisitions
    • Support from Regulatory Authorities
    • Alliances Between Diagnostics and Technology-Based Companies
  • Regulatory Environment and Advances in MDx
  • Key Players in the MDx Field
    • Roche Diagnostics
    • Abbott Diagnostics
    • Bayer Diagnostics/Siemens Medical Solutions Group
  • Market Outlook

Tables:

  • 1. Select Molecular Diagnostics for Infectious Agents
  • 2. The Third Phase of the MDx Industry
  • 3. Recent Alliances Between Research Organizations and Pharmaceutical/Biotech Companies
  • 4. AmpliChip CYP450 Test
  • 5. Select PGx-Based Diagnostic Tests
  • 6. Comparison of Molecular Tests
  • 7. Select Pharma-Diagnostics Industry Alliances
  • 8. Recent Alliances Between Diagnostic and Technology Companies
  • 9. Key Mergers and Acquisitions in the MDx Market
  • 10. Likely Impact of Increased Uptake of MDx Tests
  • 11. Global Market Opportunities for Molecular Diagnostics, 2005-2010
  • A. Current and Planned MDx Products at Celera Diagnostics

Figures:

  • 1. The Three Phases of the Molecular Diagnostic Industry
  • 2. Growth in Alliances Between Academia/Research Organizations and Pharmaceutical/Biotech Companies, 2002-2006
  • 3. Select Molecular Diagnostic Technologies and Platforms
  • 4. Interrelationship Between Pharmaceutical/Biotech and Molecular Diagnostics Companies
  • 5. Future Diversifi cation of the MDx Market
Back to Top